Who are Metformin + Clomiphene's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Metformin plus clomiphene citrate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metformin-clomiphene.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Metformin + Clomiphene — Competitive Intelligence Brief

Metformin + Clomiphene (Metformin + Clomiphene) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: biguanide + selective estrogen receptor modulator (SERM). Area: Reproductive endocrinology / Fertility.

marketed Combination therapy: biguanide + selective estrogen receptor modulator (SERM) Metformin: AMP-activated protein kinase (AMPK); Clomiphene: estrogen receptor (ER) Reproductive endocrinology / Fertility Small molecule Live · refreshed every 30 min

Target snapshot

Metformin + Clomiphene (Metformin + Clomiphene) — University of Auckland, New Zealand. Metformin improves insulin sensitivity and reduces hepatic glucose production, while clomiphene stimulates ovulation by blocking estrogen feedback on the hypothalamus and pituitary.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metformin + Clomiphene TARGET	Metformin + Clomiphene	University of Auckland, New Zealand	marketed	Combination therapy: biguanide + selective estrogen receptor modulator (SERM)	Metformin: AMP-activated protein kinase (AMPK); Clomiphene: estrogen receptor (ER)
Metformin plus clomiphene citrate	Metformin plus clomiphene citrate	University Magna Graecia	marketed	Combination therapy: biguanide + selective estrogen receptor modulator (SERM)	Insulin signaling pathway (metformin); estrogen receptor (clomiphene citrate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: biguanide + selective estrogen receptor modulator (SERM) class)

University Magna Graecia · 1 drug in this class
University of Auckland, New Zealand · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metformin + Clomiphene — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-clomiphene. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab